Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peanut oral immunotherapy dosing schedule for missed doses

A technology of immunotherapy and dosage, which is applied in drug combination, drug delivery, pharmaceutical formulation, etc., and can solve problems such as missed doses and dosing phases or maintenance phases

Pending Publication Date: 2022-01-04
SOC DES PROD NESTLE SA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Treated patients may occasionally miss one or more doses of immunotherapy during the boost or maintenance phase due to voluntary non-compliance, inadvertent non-compliance, or adverse reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peanut oral immunotherapy dosing schedule for missed doses
  • Peanut oral immunotherapy dosing schedule for missed doses
  • Peanut oral immunotherapy dosing schedule for missed doses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0149] Example 1: Continuing Oral Immunotherapy for Peanut Allergy

[0150] Peanut allergy in a patient with a diagnosed peanut allergy was treated by administering a peanut protein pharmaceutical formulation according to an oral immunotherapy schedule. The daily dosage levels for the dosing phase of the schedule were 3 mg, 6 mg, 12 mg, 20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 200 mg, 240 mg and 300 mg peanut protein. Each dose level for the dosing phase was indicated for two weeks of administration, as tolerated. The maintenance phase of the schedule included a daily dose level of 300 mg peanut protein, as tolerated. In the clinic, and under medical supervision, patients undergo initial dose escalation through doses of 0.5 mg, 1 mg, 1.5 mg, 3 mg, and 6 mg of peanut protein with intervals between doses of 20 to 30 minutes.

[0151] The next day, the patient returned to the clinic where she was administered a dose of 3 mg peanut protein, the first dose of the dosing schedule. ...

Embodiment 2

[0153] Example 2: Continuing Oral Immunotherapy for Peanut Allergy

[0154]Peanut allergy in a patient with a diagnosed peanut allergy was treated by administering a peanut protein pharmaceutical formulation according to an oral immunotherapy schedule. The daily dosage levels for the dosing phase of the schedule were 3 mg, 6 mg, 12 mg, 20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 200 mg, 240 mg and 300 mg peanut protein. Each dose level for the dosing phase was indicated for two weeks of administration, as tolerated. The maintenance phase of the schedule included a daily dose level of 300 mg peanut protein, as tolerated. In the clinic, and under medical supervision, patients undergo initial dose escalation through doses of 0.5 mg, 1 mg, 1.5 mg, 3 mg, and 6 mg of peanut protein with intervals between doses of 20 to 30 minutes.

[0155] The next day, the patient returned to the clinic where she was administered a dose of 3 mg peanut protein, the first dose of the dosing schedule. P...

Embodiment 3

[0157] Example 3: Continuation of Oral Immunotherapy for Peanut Allergy

[0158] Peanut allergy in a patient with a diagnosed peanut allergy was treated by administering a peanut protein pharmaceutical formulation according to an oral immunotherapy schedule. The daily dosage levels for the dosing phase of the schedule were 3 mg, 6 mg, 12 mg, 20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 200 mg, 240 mg and 300 mg peanut protein. Each dose level for the dosing phase was indicated for two weeks of administration, as tolerated. The maintenance phase of the schedule included a daily dose level of 300 mg peanut protein, as tolerated. In the clinic, and under medical supervision, patients undergo initial dose escalation through doses of 0.5 mg, 1 mg, 1.5 mg, 3 mg, and 6 mg of peanut protein with intervals between doses of 20 to 30 minutes.

[0159] The next day, the patient returned to the clinic where she was administered a dose of 3 mg peanut protein, the first dose of the dosing schedu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates to improved oral immunotherapy methods for treating peanut allergy. In certain embodiments, the disclosure provides methods for continuing an oral immunotherapy for the treatment of a peanut allergy after missing a scheduled oral administration of one or more consecutive doses of a pharmaceutical composition comprising peanut protein.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to U.S. Provisional Application No. 62 / 783,102, filed December 20, 2018, the contents of which are hereby incorporated by reference in their entirety. technical field [0003] Described herein is a method for continuing oral immunotherapy for the treatment of peanut allergy after the patient being treated misses one or more consecutive doses on a dosing schedule. Background technique [0004] Peanut allergy is an allergic, hypersensitivity reaction of the immune system to peanut protein. Peanut allergy usually develops in childhood and is often a lifelong affliction. Allergic reactions to peanuts can be serious and life-threatening, and are a major source of severe food-induced anaphylaxis. [0005] Until recently, the standard of care for the management of peanut allergy consisted of dietary elimination and avoidance of peanuts, education about the signs of anaphylaxis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/00A61K36/48A61K39/35
CPCA61K39/35A61K36/48A61K2039/542A61K2039/545A61P37/08A61K9/0053A61K38/168
Inventor J·G·马修斯K·R·布朗A·拉特纳亚克D·阿德尔曼
Owner SOC DES PROD NESTLE SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com